DRMA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Dermata Therapeutics Inc (DRMA) is not a good buy for a beginner investor with a long-term strategy at this time. The stock shows bearish technical indicators, lacks positive catalysts, and has no recent signals from Intellectia Proprietary Trading Signals. Additionally, analysts have lowered the price target significantly due to share dilution, and there are no recent news or insider activities to suggest a turnaround. Given the investor's preference for long-term stability and growth, this stock does not align with their goals.
The technical indicators for DRMA are bearish. The MACD is negatively expanding, the RSI is neutral at 41.722, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock closed at $1.197, below the pivot level of $1.249, and is approaching the first support level (S1: $1.173).
No positive catalysts identified. There is no recent news, and hedge funds and insiders are neutral with no significant trading trends.
Technical indicators are bearish, and the stock is projected to decline further in the next month (-8.48%).
No financial data available for analysis. The company's Q4 results indicate operating expenses slightly below estimates but a wider GAAP loss per share.
Maxim has lowered the price target from $10 to $4, maintaining a Buy rating. However, the reduction reflects share dilution and wider-than-expected losses, which are negative signals for long-term investors.
